A new pan-European study is pulling the spotlight from drug chemistry to clinician psychology—showing that whether healthcare professionals prescribe novel, non-routine therapies for neurodegenerative diseases often hinges on behavioural barriers as much as on clinical evidence.
Researchers from Alpharmaxim and Aston University, working as part of a Knowledge Transfer Partnership funded by Innovate UK, surveyed 279 healthcare professionals across Europe. The analysis probed how psychological constructs and real-world constraints combine to shape prescribing decisions.
The study forms the third and final paper in a three-part programme. Earlier work triangulated likely intervention routes through evidence synthesis and expert consensus, setting the stage for this cross-sectional statistical test of theory-based predictors.
Even when a new medication is backed by strong evidence, uptake can stall. The paper highlights why: negative experiences with prior “breakthrough” drugs, ingrained prescribing habits, and uncertainty about patient outcomes can quietly reduce adoption despite favourable data.
Disease stage also matters. In early disease, clinicians tend to remain anchored to existing guidelines and routine protocols. As disease advances, the perceived need for change increases, making clinicians more likely to consider newer or less typical therapies.
Crucially, the researchers identify four main influences on prescribing behaviour: clinicians’ confidence in their skills, opportunity (including guidance availability and access), motivation, and intention—defined as conscious readiness to prescribe.
The strongest behavioural lever, the authors argue, is shifting intention. That means interventions should not only present evidence, but also reshape beliefs about outcomes and address perceived barriers through practical support.
Training, decision-support tools, and clear, easily accessible guidelines are proposed as mechanisms that can convert willingness into action. At the same time, system-level alignment improves “opportunity,” reducing friction between policy, practice, and access to treatments.
The authors describe the broader significance as a move toward behavioural diagnostics. Their findings feed into the Healthcare Behavioural Insights Tool (H-BIT), designed to identify the specific behavioural bottlenecks that block translation of research into patient care.
In short, the path to transformative therapies may depend less on what clinicians know, and more on how they’re supported to decide, commit, and prescribe.
Subject of Research: People
Article Title: Theory-based predictors of prescribing behaviour for neurodegenerative diseases: A cross-sectional survey with European healthcare professionals
News Publication Date: 15-Jul-2026
Web References: https://doi.org/10.1371/journal.pone.0353479
References: https://doi.org/10.1371/journal.pone.0353479
Image Credits: N/A
Keywords: neurodegenerative diseases, prescribing behaviour, behavioural psychology, intention to prescribe, decision support, clinical guidelines
